AR048602A1 - Compuestos alquinicos con actividad antagonista de mch y medicamentos que contienen estos compuestos - Google Patents

Compuestos alquinicos con actividad antagonista de mch y medicamentos que contienen estos compuestos

Info

Publication number
AR048602A1
AR048602A1 ARP050101440A ARP050101440A AR048602A1 AR 048602 A1 AR048602 A1 AR 048602A1 AR P050101440 A ARP050101440 A AR P050101440A AR P050101440 A ARP050101440 A AR P050101440A AR 048602 A1 AR048602 A1 AR 048602A1
Authority
AR
Argentina
Prior art keywords
chlorophenyl
ethynyl
pyridin
ethyl
methyl
Prior art date
Application number
ARP050101440A
Other languages
English (en)
Inventor
Dirk Stenkamp
Stephan Georg Mueller
Philipp Lustenberger
Thorsten Lehmann-Lintz
Gerald Juergen Roth
Klaus Rudolf
Marcus Schindler
Leo Thomas
Ralf Lotz
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR048602A1 publication Critical patent/AR048602A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms

Abstract

La presente se refiere a compuestos alquínicos individuales con actividad antagonista sobre el receptor de MCH, que son adecuados para la fabricacion de medicamentos para el tratamiento de trastornos metabolicos y/ o trastornos alimentarios, en especial de la adiposidad y diabetes. Reivindicacion 1: Compuesto alquínico seleccionado de la lista: (2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-metil-fenoxi}-etil)-ciclopropilmetil-amina, (2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-metil- fenoxi}-etil)-ciclopentil-amina; (2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-metil-fenoxi}-etil)-ciclopentilmetil-amina; 5-(4-clorofenil)-2-{4-[2-((S)-2-metoxi-metil-pirrolidin-1-il)-etoxi]-3-metil-feniletinil]-piridina; 5-(4-clorofenil)-2-{4-[2- ((R)-2-metoxi-metil-pirrolidin-1-il)-etoxi]-3-metil-feniletinil]-piridina; 1-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-metil-fenoxi}-etil)-4-trifluorometil-piperidin-4-ol; 1-[1-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-metil-fenoxi}-etil)- piperidin-4-il]-2,2,2-trifluoro-etanol; 1-[1-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-metil-fenoxi}-etil)-piperidin-4-il]-2,2,2-trifluoro-etanona; (2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-metil-fenoxi}-etil)-ciclohexil-ciclopentil-amina; (3S,4R)-1-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-metil-fenoxi}-etil-4-trifluorometil-piperidin-3,4-diol; (3R,4S)-1-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-metil-fenoxi}-etil-4-trifluorometil-piperidin-3,4-diol; 2-(2-{4-[5-(4- clorofenil)-piridin-2-il-etinil]-2-metil-fenoxi}-etilamino)-2-metil-propan-1-ol; [1-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-metil-fenoxi}-etilamino)-ciclopentil]-metanol, 1-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-metil-fenoxi}-etil)-4- isopropil-piperidin-4-ol; (1R, 3R, 5S)-8-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-metil-fenoxi}-etil)-3-metil-8-aza-biciclo[3.2.1]octan-3-ol; (1R, 3R, 5S)-8-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-metil-fenoxi}-etil-3-etil-8-aza- biciclo[3.2.1]octan-3-ol; (1R, 3S, 5S)-8-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-metil-fenoxi}-etil-3-trifluorometil-8-aza-biciclo[3.2.1]octan-3-ol; (1R, 3R, 5S)-8-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-metil-fenoxi}-etil-3- trifluorometil-8-aza-biciclo[3.2.1]octan-3-ol; 1-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-metil-fenoxi}-etil)-4-etil-piperidin-4-ol; (2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-metil-fenoxi} -etil)-ciclohexil-ciclopropilmetil-amina; (2-{4- [5-(4-clorofenil)-piridin-2-il-etinil]-2-metil-fenoxi}-etil)-diciclopentil-amina; (2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-metil-fenoxi}-etil)-ciclopentil-ciclopropilmetil-amina; (2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-metil-fenoxi}- etil)-ciclopentilmetil-ciclopropilmetil-amina; (2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-metil-fenoxi}-etil)-ciclopentil-ciclopentilmetil-amina; (2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-metil-fenoxi}-etil)-ciclohexil-ciclopentilmetil- amina; 2-[2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-metil-fenoxi}-etil)-ciclopentil-amino]-etanol; 3-[(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-metil-fenoxi}-etil)-ciclopentil-amino]-propan-1-ol; 3-[(2-{4-[5-(4-clorofenil)-piridin-2-il- etinil]-2-metil-fenoxi}-etil)-ciclopentilmetil-amino]-propan-1-ol; 2-[(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-metil-fenoxi}-etil)-ciclopentilmetil-amino]-etanol; (2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-metil-fenoxi}-etil)-ciclohexil- ciclopropilmetil-amina; 1-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-fenoxi}-etil)-4-trifluorometil-piperidin-4-ol; 1-[1-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-fenoxi}-etil)-piperidin-4-il]-2,2,2-trifluoro-etanol; 1-[1-(2-{4-[5-(4- clorofenil)-piridin-2-il-etinil]-fenoxi}-etil)-piperidin-4-il]-2,2,2-trifluoro-etanona; (2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-fenoxi}-etil-ciclopropilmetil-propil-amina; (3S, 4R)-1-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-fenoxi}-etil)-4- trifluorometil-piperidin-3,4-diol; (3R, 4S)-1-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-fenoxi}-etil)-4-trifluorometil-piperidin-3,4-diol; 8-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-fenoxi}-etil)-3-metil-8-aza-biciclo[3.2.1]octan-3-ol; 8-(2- {4-[5-(4-clorofenil)-piridin-2-il-etinil]-fenoxi}-etil)-3-etil-8-aza-biciclo[3.2.1]octan-3-ol; exo-8-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-fenoxi}-etil)-3-trifluorometil-8-aza-biciclo[3.2.1]octan-3-ol; endo-8-(2-{4-[5-(4-clorofenil)-piridin- 2-il-etinil]-fenoxi}-etil)-3-trifluorometil-8-aza-biciclo[3.2.1]octan-3-ol; ( R )-2-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-fenoxi}-etilamino)-propan-1-ol; 2-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-fenoxi}-etilamino)-2-metil-propan-1-ol; [1-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-fenoxi}-etilamino)-ciclopentil]-metanol; 1-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-fenoxi}-etil)-4-isopropil-piperidin-4-ol; 1-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-fenoxi}-etil)-4-etil- piperidin-4-ol; (2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-fenoxi}-etil)-ciclopentil-ciclopropilmetil-amina; 3-[(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-fenoxi}-etil)-ciclopropilmetil-amino]-propan-1-ol; 2-[4-(2-azetidin-1-il-etoxi)-fenil- etinil]-5-(4-clorofenil)-3-fluoro-piridina; 5-(4-clorofenil)-3-fluoro-2-{4-[2-((S)-2-metoxi-metil-pirrolidin-1-il)-etoxi]-fenil-etinil}-piridina; 8-(2-{4-[5-(4-clorofenil)-3-fluoro-piridin-2-il-etinil]-fenoxi}-etil)-8-aza-biciclo[3.2.1]octan-3-ol; [1-(2-{4-[5-(4-clorofenil)-3-fluoro-piridin-2-il-etinil]-fenoxi}-etil)-piperidin-4-il]-metanol; 1-(2-{4-[5-(4-clorofenil)-3-fluoro-piridin-2-il-etinil]-fenoxi}-etil)-piperidin-3-ol; (3R, 4S)-1-(2-{4-[5-(4-clorofenil)-3-fluoro-piridin-2-il-etinil]- fenoxi}-etil)-4-metil-piperidin-3,4-diol; 1-(2-{4-[5-(4-clorofenil)-3-fluoro-piridin-2-il-etinil]-fenoxi}-etil)-4-trifluorometil-piperidin-4-ol; 1-[(S)-1-(2-{4-[5-(4-clorofenil)-3-fluoro-piridin-2-il-etinil]-fenoxi}-etil)-pirrolidin-2- il]ciclopropanol; [(S)-1-(2-{4-[5-(4-clorofenil)-3-fluoro-piridin-2-il-etinil]-2-metil-fenoxi}-etil)-pirrolidin-2-il]-metanol; 5-(4-clorofenil)-3-fluoro-2-{4-[2-((S)-2-metoxi-metil-pirrolidin-1-il)-etoxi]-3-metil-fenil-etinil}-piridina, 5-(4- clorofenil)-3-fluoro-2-{3-metil-4-[2-(4-metil-piperidin-1-il)-etoxi]-fenil-etinil}-piridina; 8-(2-{4-[5-(4-clorofenil)-3-fluoro-piridin-2-il-etinil]-2-metil-fenoxi}-etil)-8-aza-biciclo[3.2.1]octan-3-ol, 1-[(S)-1-(2-{4-[5-(4-clorofenil)-3-fluoro- piridin-2-il-etinil]-2-metil-fenoxi}-etil)-pirrolidin-2-il]-ciclopropanol; 1-(2-{4-[5-(4-clorofenil)-3-fluoro-piridin-2-il-etinil]-2-metil-fenoxi}-etil)-4-metil-piperidin-4-ol; [(S)-1-(2-{2-bromo-4-[5-(4-clorofenil)-3-fluoro-piridin-2-il-etinil]- fenoxi}-etil)-pirrolidin-2-il]-metanol; 1-[(S)-1-(2-{2-bromo-4-[5-(4-clorofenil)-3-fluoro-piridin-2-il-etinil]-fenoxi}-etil)-pirrolidin-2-il]-ciclopropanol; 2-{3-bromo-4-[2-((S)-2-metoxi-metil-pirrolidin-1-il)-etoxi]-fenil-etinil}-5-(4-clorofenil)-3- fluoro-piridina; 1-(2-{2-bromo-4-[5-(4-clorofenil)-3-fluoro-piridin-2-il-etinil]-fenoxi}-etil)-4-metil-piperidin-4-ol; 2-{3-bromo-4-[2-(4-metil-piperidin-1-il)-etoxi]-fenil-etinil}-5-(4-clorofenil)-3-fluoro-piridina; 8-(2-{2-bromo-4-[5-(4- clorofenil)-3-fluoro-piridin-2-il-etinil]-fenoxi}-etil)-8-aza-biciclo[3.2.1]octan-3-ol; 5-[5-(4-clorofenil)-piridin-2-il-etinil]-1-[2-(4-metil-piperidin-1-il)-etil]-1H-indazol; [(S)-1-(2-{5-[5-(4-clorofenil)-piridin-2-il-etinil]-indazol-1-il}-etil)- pirrolidin-2-il]-metanol; 1-(2-{5-[5-(4-clorofenil)- piridin-2-il-etinil]-indazol-1-il}-etil)-4-metil-piperidin-4-ol; 5-[5-(4-clorofenil)- piridin-2-il-etinil]-1-[2-(2,6-dimetil-piperidin-1-il)-etil]-1H-indazol; 5-(4-clorofenil)-2-{4-[2-(4-metil- piperidin-1-il)-etoxi]-3-vinil-fenil-etinil}-piridina; 1-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-vinil-fenoxi}-etil)-4-metil-piperidin-4-ol; [(S)-1-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-vinil-fenoxi}-etil)-pirrolidin-2-il]-metanol; 5- (4-clorofenil)-2-{4-[2-(4,4-dimetil-piperidin-1-il)-etoxi]-3-vinil-fenil-etinil}-piridina; 5-(4-clorofenil)-2-{3-isopropenil-4-[2-(4-metil-piperidin-1-il)-etoxi]-fenil-etinil}-piridina; [(S)-1-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2- isopropenil-fenoxi}-etil)-pirrolidin-2-il]-metanol; 1-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-isopropenil-fenoxi}-etil)-4-metil-piperidin-4-ol; 5-(4-clorofenil)-2-{4-[2-(4,4-dimetil-piperidin-1-il)-etoxi]-3-isopropenil-fenil-etinil}-piridina; 1-(2-{4-[5-(4-clorofenil)-piridin-2-il-etinil]-2-isopropenil-fenoxi}-etil)-4-trifluorometil-piperidin-4-ol; 1-{5-[5-(4-clorofenil)-piridin-2-il-etinil]-2-[2-(4-metil-piperidin-1-il)-etoxi]-fenil}-etanona; 1-{5-[5-(4-clorofenil)-piridin-2-il-etinil]- 2-[2-((S)-2-hidroximetil-pirrolidin-1-il)-etoxi]-fenil}-etanona; 1-{5-[5-(4-clorofenil)-piridin-2-il-etinil]-2-[2-(4-hidroxi-4-metil-piperidin-1-il)-etoxi]-fenil}-etanona; 1-{5-[5-(4-clorofenil)-piridin-2-il-etinil]-2-[2-(4,4-dimetil-piperidin-1-il)- etoxi]-fenil}-etanona; 1-{5-[5-(4-clorofenil)-piridin-2-il-etinil]-2-[2-(4-hidroxi-4-trifluorometil-piperidin-1-il)-etoxi]-fenil}-etanona; 5-[5-(4-clorofenil)-piridin-2-il-etinil]-2-[2-(4-metil-piperidin-1-il)-etoxi]-benzaldehído-O-metil-oxima; 5-[5- (4-clorofenil)-piridin-2-il-etinil]-2-[2-((S)-2-hidroximetil-pirrolidin-1-il)-etoxi-benzaldehído-O-metil-oxima; 5-[5-(4-clorofenil)-piridin-2-il-etinil]-2-[2-(4-hidroxi-piperidin-1-il)-etoxi]- benzaldehído-O-metil-oxima; 5-[5-(4-clorofenil)-piridin- 2-il-etinil]-2-[2-(2,6-dimetil-piperidin-1-il)-etoxi]- benzaldehído-O-metil-oxima; 5-[5-(4-clorofenil)-piridin-2-il-etinil]-2-[2-(3,5-dimetil-piperidin-1-il)-etoxi]-benzaldehído-O-metil-oxima, 5-[5-(4-clorofenil)-piridin-2-il-etinil]-2-[2-(4-metil- piperidin-1-il)-etoxi]- benzaldehído-oxima; 5-[5-(4-clorofenil)-piridin-2-il-etinil]-2-[2-((S)-2-hidroximetil-pirrolidin-1-il)-etoxi]- benzaldehído-oxima; 5-[5-(4-clorofenil)-piridin-2-il-etinil]-2-[2-(4-hidroxi-piperidin-1-il)-etoxi- benzaldehído- oxima; 5-[5-(4-clorofenil)-piridin-2-il-etinil]-2-[2-(2,6-dimetil-piperidin-1-il)-etoxi] benzaldehído-oxima; 5-[5-(4-clor
ARP050101440A 2004-04-14 2005-04-13 Compuestos alquinicos con actividad antagonista de mch y medicamentos que contienen estos compuestos AR048602A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004017934A DE102004017934A1 (de) 2004-04-14 2004-04-14 Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
AR048602A1 true AR048602A1 (es) 2006-05-10

Family

ID=34981978

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101440A AR048602A1 (es) 2004-04-14 2005-04-13 Compuestos alquinicos con actividad antagonista de mch y medicamentos que contienen estos compuestos

Country Status (10)

Country Link
US (1) US7592358B2 (es)
EP (1) EP1737823A2 (es)
JP (1) JP2007532595A (es)
AR (1) AR048602A1 (es)
CA (1) CA2559688A1 (es)
DE (1) DE102004017934A1 (es)
PE (1) PE20060174A1 (es)
TW (1) TW200536516A (es)
UY (1) UY28849A1 (es)
WO (1) WO2005103002A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452911B2 (en) 2002-10-31 2008-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE102004017935A1 (de) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20060046969A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Antibacterial compositions for drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US20060046962A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
EP1789075A4 (en) * 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
WO2008022979A1 (en) 2006-08-25 2008-02-28 Boehringer Ingelheim International Gmbh New pyridone derivatives with mch antagonistic activity and medicaments comprising these compounds
JP2010512366A (ja) 2006-12-11 2010-04-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｃｈ拮抗活性を有する新規ピリダジン誘導体及びこれらの化合物を含む薬物
US8263585B2 (en) * 2007-05-04 2012-09-11 Novartis Ag Organic compounds
KR20100028068A (ko) * 2007-07-03 2010-03-11 사노피-아벤티스 말단 알킨과 헤테로아릴 토실레이트 및 헤테로아릴 벤젠설포네이트의 팔라듐-촉매되는 커플링 방법
KR101133862B1 (ko) * 2007-07-27 2012-04-06 에프. 호프만-라 로슈 아게 Ｔａａｒ 리간드로서의 2-아제티딘메테인아민 및 2-피롤리딘메테인아민
US8268834B2 (en) * 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
JP5613657B2 (ja) 2008-03-28 2014-10-29 ヘイル バイオファーマ ベンチャーズ，エルエルシー ベンゾジアゼピン組成物の投与
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
CN107737100A (zh) 2011-06-14 2018-02-27 哈尔生物药投资有限责任公司 苯二氮卓组合物的投与
AU2014334040A1 (en) 2013-10-07 2016-04-28 Bayer Pharma Aktiengesellschaft Cyclic thienouracil-carboxamides and use thereof
EA202091615A1 (ru) 2018-12-21 2021-03-05 Аегис Терапьютикс, Ллс Интраназальные составы на основе эпинефрина и способы лечения заболевания

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8530507D0 (en) 1985-12-11 1986-01-22 Glaxo Group Plc Chemical compounds
JPH0454118A (ja) 1990-06-20 1992-02-21 Tanabe Seiyaku Co Ltd ５―リポキシゲナーゼ阻害剤
CA2276278C (en) 1997-02-27 2009-04-07 Takeda Chemical Industries, Ltd. Amine compounds, their production and use
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
WO1999029674A1 (en) 1997-12-11 1999-06-17 Janssen Pharmaceutica N.V. Retinoic acid mimetic anilides
JP2000086603A (ja) 1998-07-15 2000-03-28 Yoshitomi Pharmaceut Ind Ltd 桂皮酸アミド誘導体および３―フェニルプロピオン酸アミド誘導体
WO2000005223A2 (en) 1998-07-23 2000-02-03 Astrazeneca Ab Heterocyclic derivatives and their use as integrin inhibitors
WO2000006153A1 (en) 1998-07-28 2000-02-10 Smithkline Beecham Corporation Propenamides as ccr5 modulators
DE60027700T2 (de) 1999-02-16 2007-05-03 Aventis Pharma Ltd., West Malling Bicyclische verbindungen und ihre verwendung als integrinrezeptorliganden
WO2001002344A1 (fr) 1999-07-01 2001-01-11 Taisho Pharmaceutical Co., Ltd. Derives d'acide aminobenzoique
AU7315700A (en) * 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Melanin concentrating hormone antagonist
US6366268B1 (en) 1999-12-03 2002-04-02 The Trustees Of Princeton University Display driving method and device
BR0107770A (pt) 2000-01-25 2003-04-29 Syngenta Participations Ag Derivados de 3-fenóxi-1-fenil acetileno e seu uso como herbicidas
EP1285651B1 (en) 2000-04-28 2010-09-01 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonists
CA2408913A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
JP2004504303A (ja) 2000-07-05 2004-02-12 シナプティック・ファーマスーティカル・コーポレーション 選択的メラニン凝集ホルモン−１（ｍｃｈ１）受容体アンタゴニストおよびその使用
EP1366030A2 (en) 2000-07-06 2003-12-03 Neurogen Corporation Melanin concentrating hormone receptor ligands
AU2002218200B2 (en) 2000-10-03 2004-08-05 Syngenta Participations Ag Phenylpropynyloxypyridine herbicides
US20030022891A1 (en) 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
DE60112791T2 (de) 2000-12-22 2006-06-08 Schering Corp. Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität
ATE416762T1 (de) 2001-05-10 2008-12-15 Ono Pharmaceutical Co Carbonsäurederivate und diese als wirkstoff enthaltende arzneimittel
GB0119474D0 (en) 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
AR035087A1 (es) 2001-08-09 2004-04-14 Syngenta Participations Ag Piridil-alquinos y piridil-n-oxido-alquinos herbicidas activos, procedimiento para su preparacion, composicion herbicida y para inhibir el crecimiento de plantas, metodo para el control del crecimiento de plantas indeseables , y metodo para la inhibicion del crecimiento de plantas
JO2311B1 (en) 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
GB0124627D0 (en) 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
GB0124931D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
EP1443922A1 (en) 2001-10-25 2004-08-11 Schering Corporation Mch antagonists for the treatment of obesity
AR037754A1 (es) 2001-12-11 2004-12-01 Syngenta Participations Ag Herbicidas
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
DE10250708A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7452911B2 (en) * 2002-10-31 2008-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
WO2004072018A1 (ja) 2003-02-12 2004-08-26 Takeda Pharmaceutical Company Limited アミン誘導体
DE102004017935A1 (de) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel

Also Published As

Publication number Publication date
US7592358B2 (en) 2009-09-22
TW200536516A (en) 2005-11-16
WO2005103002A2 (de) 2005-11-03
DE102004017934A1 (de) 2005-11-03
WO2005103002A3 (de) 2006-02-02
UY28849A1 (es) 2005-11-30
PE20060174A1 (es) 2006-04-12
US20050234101A1 (en) 2005-10-20
CA2559688A1 (en) 2005-11-03
EP1737823A2 (de) 2007-01-03
JP2007532595A (ja) 2007-11-15

Similar Documents

Publication Publication Date Title
AR048602A1 (es) Compuestos alquinicos con actividad antagonista de mch y medicamentos que contienen estos compuestos
DE602006000339T2 (de) Substituierte pyridinyl und pyrimidinyl derivate als modulatoren eines metabolismus für die behandlung von damit inzusammenhangstehenden krankheiten
JP6122846B2 (ja) 金属酵素阻害剤化合物
RU2497526C2 (ru) Производные бензилбензола и способы их применения
EP2788343B1 (en) Metalloenzyme inhibitor compounds
PE20130315A1 (es) Mezclas fungicidas
HRP20171991T1 (hr) Derivati pirolidin karbonske kiseline kao agonisti g-protein spojenog receptora (gpr43), farmaceutski pripravak i postupci za primjenu u liječenju poremećaja metabolizma
NZ630488A (en) Piperidine derivatives for gpr119 agonist
EA024106B1 (ru) Производные 2-(1,2,3-триазол-2-ил)бензамида и 3-(1,2,3-триазол-2-ил)пиколинамида
PE20081891A1 (es) Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
EA025406B1 (ru) Соединения, ингибирующие металлоферменты
CL2013000884A1 (es) El compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino, modulador del factor de crecimiento de fibroblastos (fgf); composicion farmaceutica, util en el tratamiento del cancer.
PE20070522A1 (es) 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo como inhibidor de dipeptidil peptidasa y composiciones farmaceuticas que lo contienen
WO2006009149A1 (ja) 肝臓脂肪の異常蓄積に起因する疾患の進展抑制剤
SI2896397T1 (en) New compounds with inhibitory activity against a sodium-dependent glucose conveyor
HRP20120685T1 (hr) Derivati indola kao agonisti receptora s1p1
JP2006518763A5 (es)
TW200538102A (en) New alkyne compounds with mch antagonistic activity and medicaments comprising these compounds
JP2014520809A5 (es)
JP2008540683A5 (es)
CL2014000125A1 (es) Compuesto fungicidas de 1-(2-(2-halo-4-(4-halogen-fenoxi)-fenil)-2-etoxi-etil)-1h-(1,2,4)triazol sustituidos; procesos para preparar dichos compuestos; uso de dichos compuestos para combatir hongos fitopatógenos.
JP2010508338A5 (es)
MX2014001669A (es) Compuestos de fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-feni l]-2-alcoxi-2-alquinil/alquenil-etil}-1h-[1,2,4]triazol sustituidos.
AR088121A1 (es) Derivados de 4-(5-ciano-pirazol-1-il)-piperidina como moduladores de gpr119
BRPI0808838A2 (pt) Administração semanal de inibidores de depeptidil peptidase

Legal Events

Date Code Title Description
FB Suspension of granting procedure